The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials

• Published in: Obesity reviews Vol. 17; no. 12; pp. 1329 - 1340
• Main Authors: Huang, Haohai, Chen, Guangzhao, Liao, Dan, Zhu, Yongkun, Pu, Rong, Xue, Xiaoyan
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.12.2016; Wiley Subscription Services, Inc
• Subjects: adults; Biomarkers - blood; Blood pressure; Blood Pressure - drug effects; Body Mass Index; Body weight; Cardiovascular diseases; Cardiovascular Diseases - drug therapy; Cardiovascular risk factors; Cholesterol; Cholesterol - blood; confidence interval; diastolic blood pressure; disease control; glucose; Health risks; Heterogeneity; Humans; insulin; Insulin Resistance; Meta-Analysis as Topic; obesity; Obesity - drug therapy; overweight; Overweight - drug therapy; randomized clinical trials; Randomized Controlled Trials as Topic; Reproducibility of Results; resveratrol; Risk Factors; Stilbenes - administration & dosage; Stilbenes - blood; systolic blood pressure; Cardiovascular risk factors; overweight; resveratrol; obesity
• ISSN: 1467-7881; 1467-789X; 1467-789X
• DOI: 10.1111/obr.12458

Background Potential effects of resveratrol consumption on cardiovascular disease risk factors and body weight in overweight/obese adults have not been fully elucidated. Our present analysis was to evaluate the effects of resveratrol consumption on risk markers related to cardiovascular health in overweight/obese Individuals. Methods Multiple literature databases were systematically searched, and 21 studies were included. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI), and heterogeneity was assessed with the I2 test. Publication bias and subgroup analyses were also performed. Results There were variations in reporting quality of included studies. Resveratrol intervention significantly lowered total cholesterol (WMD, –0.19 mmol/L; 95% CI, –0.32 to –0.06; P = 0.004), systolic blood pressure (WMD, –2.26 mmHg; 95% CI, –4.82 to –0.49; P = 0.02), and fasting glucose (WMD, –0.22 mmol/L; 95% CI, –0.42 to –0.03; P = 0.03). Heterogeneity was noted for these outcomes (35.6%, 38.7% and 71.4%, respectively). Our subgroup analysis showed significant reductions in total cholesterol, systolic blood pressure, diastolic blood pressure, glucose, and insulin in subjects ingesting higher dose of resveratrol (≥300 mg/day). Conclusion Our finding provides evidence that daily resveratrol consumption might be a candidate as an adjunct to pharmacological management to better prevent and control cardiovascular disease in overweight/obese individuals.